miRagen Therapeutics to Present New Clinical Trial Data for MRG-106, an Oligonucleotide Therapeutic Targeting microRNA-155, a...
May 17 2017 - 5:05PM
Miragen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage
biopharmaceutical company focused on the discovery and development
of microRNA-targeted therapies, announced today that new interim
results from its ongoing Phase 1 clinical study of MRG-106 will be
presented on June 5, 2017 at the American Society of Clinical
Oncology (ASCO) Annual Meeting being held June 2-6, 2017 in
Chicago, Illinois.
MRG-106 is an inhibitor of microRNA-155. In CTCL,
as well as certain other blood cancers, microRNA-155 is present at
abnormally high levels and plays a role in the proliferation of
blood and lymph cells. miRagen believes therapeutic inhibition of
microRNA-155 can reduce aberrant cell proliferation and tumor
growth that is characteristic of certain types of cancer.
“We look forward to presenting updated data from our ongoing
Phase 1 trial evaluating MRG-106 in patients suffering from MF, a
serious and sometimes disfiguring form of CTCL, at this year’s ASCO
Annual Meeting,” said miRagen President and Chief Executive
Officer, William S. Marshall, Ph.D. “The study being presented is
an example of our commitment to developing innovative product
candidates to treat serious diseases for which there are few, if
any, viable therapeutic options. We believe that the experience
gained in developing MRG-106 for MF may also allow us to address
other indications where microRNA-155 is implicated in disease.”
Poster Presentation DetailsAbstract
title: Phase 1 trial evaluating MRG-106, a synthetic
inhibitor of microRNA-155, in patients with cutaneous t-cell
lymphoma (CTCL)
- Poster session: Hematologic Malignancies –
Lymphoma and Chronic Lymphocytic Leukemia
- Poster number: 326
- Date: Monday, June 5, 2017, 8:00 a.m. - 11:30
a.m. CT
- Location: Hall A
For additional information, please visit the ASCO website:
www.asco.org
About miRagen Therapeutics, Inc.
miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical
company discovering and developing proprietary RNA-targeted
therapies with a specific focus on microRNAs and their role in
diseases where there is a high unmet medical need. miRagen’s two
lead product candidates, MRG-106 and MRG-201, are currently in
Phase 1 clinical trials. miRagen’s clinical product candidate for
the treatment of certain cancers, MRG-106, is an inhibitor of
microRNA-155, which is found at abnormally high levels in several
blood cancers. miRagen’s clinical product candidate for the
treatment of pathological fibrosis, MRG-201, is a replacement for
microRNA-29, which is found at abnormally low levels in a number of
pathological fibrotic conditions, including cutaneous, cardiac,
renal, hepatic, and pulmonary fibrosis, as well as systemic
sclerosis. In addition to miRagen’s clinical programs, it is
developing a pipeline of pre-clinical product candidates. The goal
of miRagen’s translational medicine strategy is to progress rapidly
to first in human studies once it has established the
pharmacokinetics, pharmacodynamics and safety of the product
candidate in pre-clinical studies. For more information, please
visit www.miragenrx.com.
For information on clinical trials please visit
www.clinicaltrials.gov.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, including statements regarding
miRagen’s strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management or the expected features of or potential indications
for miRagen’s product candidates are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation: that
miRagen has incurred losses since its inception, and anticipates
that it will continue to incur significant losses for the
foreseeable future; future financing activities may cause miRagen
to restrict its operations or require it to relinquish rights;
miRagen may fail to demonstrate safety and efficacy of its product
candidates; miRagen’s product candidates are unproven and may never
lead to marketable products; miRagen’s product candidates are based
on a relatively novel technology, which makes it difficult to
predict the time and cost of development and of subsequently
obtaining regulatory approval, if at all; and miRagen’s product
candidates may cause undesirable side effects or have other
properties that could delay or prevent the regulatory approval.
miRagen has based these forward-looking statements largely on
its current expectations and projections about future events and
trends. These forward-looking statements are subject to a number of
risks, uncertainties and assumptions, including those described
under the heading “Risk Factors” in miRagen’s Annual Report on Form
10-K and subsequent periodic reports filed with the Securities and
Exchange Commission. Moreover, miRagen operates in a very
competitive and rapidly changing environment. New risks emerge from
time to time. It is not possible for its management to predict all
risks, nor can it assess the impact of all factors on its business
or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in
any forward-looking statements it may make. In light of these
risks, uncertainties and assumptions, the future events and trends
discussed in this press release may not occur and actual results
could differ materially and adversely from those anticipated or
implied in the forward-looking statements. miRagen undertakes no
obligation to revise or publicly release the results of any
revision to such forward-looking statements, except as required by
law. Given these risks and uncertainties, readers are cautioned not
to place undue reliance on such forward-looking statements. All
forward-looking statements are qualified in their entirety by this
cautionary statement.
Investor/Media Contact:
Adam Levy
Chief Business Officer
(720) 407-4595
alevy@miragenrx.com
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024